New Animal Drugs; Ractopamine, 56896-56898 [E7-19732]
Download as PDF
<![CDATA[
56896
Federal Register / Vol. 72, No. 193 / Friday, October 5, 2007 / Rules and Regulations
Collegeville, PA, Perkiomen Valley, RNAV
(GPS) RWY 9, Amdt 1
Du Bois, PA, Du Bois-Jefferson County,
RNAV (GPS) RWY 7, Orig
Du Bois, PA, Du Bois-Jefferson County, VOR/
DME RNAV OR GPS RWY 7, Amdt 1,
CANCELLED
Du Bois, PA, Du Bois-Jefferson County,
Takeoff Minimums and Obstacle DP, Orig
Cotulla, TX, Cotulla-La Salle County, VOR–
A, Amdt 13
Cotulla, TX, Cotulla-La Salle County, Takeoff
Minimums and Obstacle DP, Orig
Farmville, VA, Farmville Regional, Takeoff
Minimums and Obstacle DP, Orig
Huntington, WV, Tri-State/Milton J. Ferguson
Field, ILS OR LOC RWY 12, Amdt 12
Huntington, WV, Tri-State/Milton J. Ferguson
Field, ILS OR LOC RWY 30, Amdt 5
Huntington, WV, Tri-State/Milton J. Ferguson
Field, RNAV (GPS) RWY 12, Amdt 1
Huntington, WV, Tri-State/Milton J. Ferguson
Field, RADAR–1, Amdt 6
Huntington, WV, Tri-State/Milton J. Ferguson
Field, Takeoff Minimums and Obstacle DP,
Orig
[FR Doc. E7–19240 Filed 10–4–07; 8:45 am]
BILLING CODE 4910–13–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
noninfectious degenerative and/or
traumatic joint disease. The
supplemental NADA provides for a
revised food safety warning for use in
horses. The application is approved as
of September 10, 2007, and the
regulations are amended in 21 CFR
522.1850 to reflect the approval and a
current format.
Approval of this supplemental NADA
did not require review of additional
safety or effectiveness data or
information. Therefore, a freedom of
information summary is not required.
The agency has determined under
§ 25.33(a)(1) that this action is of a type
that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
This rule does not meet the definition
of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because
it is a rule of ‘‘particular applicability.’’
Therefore, it is not subject to the
congressional review requirements in 5
U.S.C. 801–808.
21 CFR Part 522
Implantation or Injectable Dosage
Form New Animal Drugs; Polysulfated
Glycosaminoglycan
Food and Drug Administration,
HHS.
yshivers on PROD1PC62 with RULES
Final rule.
SUMMARY: The Food and Drug
Administration (FDA) is amending the
animal drug regulations to reflect
approval of a supplemental new animal
drug application (NADA) filed by
Luitpold Pharmaceuticals, Inc. The
supplemental NADA provides for a
revised food safety warning on labeling
for an injectable solution of polysulfated
glycosaminoglycan used in horses.
DATES: This rule is effective October 5,
2007.
FOR FURTHER INFORMATION CONTACT:
Melanie R. Berson, Center for Veterinary
Medicine (HFV–110), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 301–827–7540, email: melanie.berson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Luitpold
Pharmaceuticals, Inc., Animal Health
Division, Shirley, NY 11967, filed a
supplement to NADA 140–901 for
ADEQUAN i.m. (polysulfated
glycosaminoglycan), an injectable
solution approved for use in horses and
dogs by veterinary prescription for
VerDate Aug<31>2005
15:23 Oct 04, 2007
Jkt 214001
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 556 and 558
Animal drugs.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Center for Veterinary Medicine, 21
CFR part 522 is amended as follows:
New Animal Drugs; Ractopamine
I
ACTION:
Dated: September 26, 2007.
Bernadette Dunham,
Deputy Director, Center for Veterinary
Medicine.
[FR Doc. E7–19729 Filed 10–4–07; 8:45 am]
List of Subjects in 21 CFR Parts 522
Food and Drug Administration
AGENCY:
(ii) Amount—(A) Intra-articular use
(carpal): 250 mg once a week for 5
weeks.
(B) Intramuscular use (carpal and
hock): 500 mg every 4 days for 28 days.
(iii) Limitations. Do not use in horses
intended for human consumption.
(2) Dogs—(i) Indications for use. For
control of signs associated with
noninfectious degenerative and/or
traumatic arthritis of canine synovial
joints.
(ii) Amount. 2 mg per pound of body
weight by intramuscular injection twice
weekly for up to 4 weeks (maximum of
8 injections).
PART 522—IMPLANTATION OR
INJECTABLE DOSAGE FORM NEW
ANIMAL DRUGS
1. The authority citation for 21 CFR
part 522 continues to read as follows:
I
Authority: 21 U.S.C. 360b.
2. Revise § 522.1850 to read as
follows:
I
§ 522.1850 Polysulfated
glycosaminoglycan.
(a) Specifications. Each 1-milliliter
(mL) ampule of solution contains 250
milligrams (mg) polysulfated
glycosaminoglycan; each 5-mL ampule
or vial contains 500 mg polysulfated
glycosaminoglycan.
(b) Sponsor. See No. 010797 in
§ 510.600(c) of this chapter.
(c) Special considerations. Federal
law restricts this drug to use by or on
the order of a licensed veterinarian.
(d) Conditions of use—(1) Horses—(i)
Indications for use. For the treatment of
noninfectious degenerative and/or
traumatic joint dysfunction and
associated lameness of the carpal and
hock joints in horses.
PO 00000
Frm 00014
Fmt 4700
Sfmt 4700
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final rule.
SUMMARY: The Food and Drug
Administration (FDA) is amending the
animal drug regulations to reflect
approval of a supplemental new animal
drug application (NADA) filed by
Elanco Animal Health. The
supplemental NADA provides for an
increased level of monensin in four-way
combination Type C medicated feeds
containing ractopamine, melengestrol,
monensin, and tylosin for heifers fed in
confinement for slaughter, a revision to
bacterial pathogen nomenclature, and
an increase in liver tolerance.
DATES: This rule is effective October 5,
2007.
FOR FURTHER INFORMATION CONTACT:
Suzanne J. Sechen, Center for Veterinary
Medicine (HFV–126), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 301–827–0221, email: suzanne.sechen@cvm.fda.gov.
SUPPLEMENTARY INFORMATION: Elanco
Animal Health, A Division of Eli Lilly
& Co., Lilly Corporate Center,
Indianapolis, IN 46285, filed a
supplement to NADA 141–233 that
provides for use of OPTAFLEXX
(ractopamine hydrochloride), MGA
(melengestrol acetate), RUMENSIN
(monensin), and TYLAN (tylosin
phosphate) Type A medicated articles to
E:\FR\FM\05OCR1.SGM
05OCR1
56897
Federal Register / Vol. 72, No. 193 / Friday, October 5, 2007 / Rules and Regulations
make dry and liquid four-way
combination Type C medicated feeds
used for increased rate of weight gain,
improved feed efficiency, and increased
carcass leanness; for prevention and
control of coccidiosis due to Eimeria
bovis and E. zuernii; for suppression of
estrus (heat); and for reduction of
incidence of liver abscesses caused by
Fusobacterium necrophorum and
Arcanobacterium (Actinomyces)
pyogenes in heifers fed in confinement
for slaughter during the last 28 to 42
days on feed. The supplemental NADA
provides for an increased level of
monensin in four-way combination
Type C medicated feeds containing
ractopamine, melengestrol, monensin,
and tylosin for heifers fed in
confinement for slaughter, a revision to
bacterial pathogen nomenclature, and
an increase in the cattle liver tolerance.
The supplemental NADA is approved as
of September 11, 2007, and the
regulations in 21 CFR 556.420 and
558.500 are amended to reflect the
approval.
In accordance with the freedom of
information provisions of 21 CFR part
20 and 21 CFR 514.11(e)(2)(ii), a
summary of safety and effectiveness
data and information submitted to
support approval of this application
may be seen in the Division of Dockets
Ractopamine in
grams/ton
*
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852, between 9
a.m. and 4 p.m., Monday through
Friday.
The agency has determined under 21
CFR 25.33(a)(2) that this action is of a
type that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
This rule does not meet the definition
of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because
it is a rule of ‘‘particular applicability.’’
Therefore, it is not subject to the
congressional review requirements in 5
U.S.C. 801–808.
1. The authority citation for 21 CFR
part 556 continues to read as follows:
I
Authority: 21 U.S.C. 342, 360b, 371.
2. In § 556.420, revise paragraph (b)(1)
to read as follows:
I
§ 556.420
21 CFR Part 556
*
*
*
*
(b) * * *
(1) Cattle—(i) Liver. 0.10 part per
million (ppm).
(ii) Muscle, kidney, and fat. 0.05 ppm.
(iii) Milk. Not required.
*
*
*
*
*
3. The authority citation for 21 CFR
part 558 continues to read as follows:
I
Animal drugs, Foods.
Authority: 21 U.S.C. 360b, 371.
21 CFR Part 558
4. In § 558.500, in the table in
paragraph (e)(2), revise paragraph
(e)(2)(x) and add paragraph (e)(2)(xi) to
read as follows:
I
Animal drugs, Animal feeds.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under the
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Center for Veterinary Medicine, 21
CFR parts 556 and 558 are amended as
follows:
I
§ 558.500
*
*
Ractopamine.
*
*
(e) * * *
(2) * * *
Indications for use
*
Monensin.
*
PART 558—NEW ANIMAL DRUGS FOR
USE IN ANIMAL FEEDS
List of Subjects
Combination in grams/
ton
*
PART 556—TOLERANCES FOR
RESIDUES OF NEW ANIMAL DRUGS
IN FOOD
*
*
Limitations
*
*
Sponsor
*
Monensin 10 to 40 to
provide 0.14 to 0.42
mg monensin/lb of
body weight, depending on severity of coccidiosis challenge, up
to 480 mg/head/day,
plus tylosin 8 to 10,
plus melengestrol acetate to provide 0.25
to 0.5 mg/head/day
Heifers fed in confinement for slaughter:
As in paragraph (e)(2)(vi) of this section; for prevention and control of coccidiosis due to Eimeria bovis and E.
zuernii; for reduction of incidence of
liver abscesses caused by
Fusobacterium necrophorum and
Arcanobacterium (Actinomyces)
pyogenes; and for suppression of estrus
(heat).
As in paragraph (e)(2)(vi) of this
section; see paragraphs
§§ 558.342(d), 558.355(d) and
558.625(c) of this chapter.
Melengestrol acetate as provided
by No. 000009 in § 510.600(c) of
this chapter.
000986
(xi) 9.8 to 24.6
yshivers on PROD1PC62 with RULES
(x) 9.8 to 24.6
Monensin 10 to 30, plus
tylosin 8 to 10, plus
melengestrol acetate
to provide 0.25 to 0.5
mg/ head/day
Heifers fed in confinement for slaughter:
As in paragraph (e)(2)(vi) of this section; for prevention and control of coccidiosis due to Eimeria bovis and E.
zuernii; for reduction of incidence of
liver abscesses caused by
Fusobacterium necrophorum and
Actinomyces (Corynebacterium)
pyogenes; and for suppression of estrus
(heat).
As in paragraph (e)(2)(vi) of this
section; see paragraphs
§§ 558.342(d), 558.355(d) and
558.625(c) of this chapter.
Melengestrol acetate as provided
by No. 021641 in § 510.600(c) of
this chapter.
021641
VerDate Aug<31>2005
15:23 Oct 04, 2007
Jkt 214001
PO 00000
Frm 00015
Fmt 4700
Sfmt 4700
E:\FR\FM\05OCR1.SGM
05OCR1
56898
Federal Register / Vol. 72, No. 193 / Friday, October 5, 2007 / Rules and Regulations
Dated: September 26, 2007.
Bernadette Dunham,
Deputy Director, Center for Veterinary
Medicine.
[FR Doc. E7–19732 Filed 10–4–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
33 CFR Part 117
[Docket No. CGD08–07–022]
Drawbridge Operation Regulations;
Milhomme Bayou, Stephensville, LA
Coast Guard, DHS.
Notice of temporary deviation
from regulations; request for comments.
Request for Comments
We encourage you to participate in
evaluating this test schedule by
submitting comments and related
material. If you do so, please include
your name and address, identify the
docket number for this deviation
[CGD08–07–022], indicate the specific
section of this document to which each
comment applies, and give the reason
for each comment. Please submit all
comments and related material in an
unbound format, no larger than 8 by 11
inches, suitable for copying. If you
would like to know they reached us,
please enclose a stamped, self-addressed
postcard or envelope. We will consider
all comments and material received
during the comment period. Comments
must be received by December 4, 2007.
Background and Purpose
ACTION:
yshivers on PROD1PC62 with RULES
AGENCY:
St. Martin Parish has requested that
the operating regulation on the
Stephensville Bridge be changed in
order to operate the bridge more
efficiently. The Stephensville Bridge is
located on Milhomme Bayou at mile
12.2 in Stephensville, St. Martin Parish,
Louisiana. The Bridge has a vertical
clearance of 5.8 feet above mean high
water, an elevation of 3.5 feet Mean Sea
Level (MSL) in the closed position and
unlimited in the open position. The
Stephensville Bridge opens on signal as
required by 33 CFR 117.5. This
operating schedule has been in effect
since 2002 when this bridge replaced an
existing bridge in the area.
The previous bridge’s operating
schedule was, ‘‘shall open on signal;
except that, from 10 p.m. to 6 a.m. the
draw shall open on signal if at least two
hours notice is given. During the
advance notice period, the draw shall
open on less than two hours notice for
an emergency and shall open on
demand should a temporary surge in
waterway traffic occur.’’
Since the completion of the current
bridge, the waterway traffic has been
minimal and during the past twelve
months an average of 5 boats per day
have requested an opening. Most of the
boats requesting openings are
commercial vessels consisting of
tugboats with barges and shrimp
trawlers that routinely transit this
waterway and are able to give advance
notice.
Due to this waterway being a
secondary route, the Port Allen
Alternate route is the primary route,
little impact is expected on navigation
during this test schedule period. Also,
prior coordination with the main
waterway user group in the area
indicates no expected impacts.
SUMMARY: The Commander, Eighth
Coast Guard District, has issued a
temporary deviation from the regulation
governing the operation of the
Stephensville Bridge across Milhomme
Bayou, mile 12.2, at Stephensville, St.
Martin Parish, Louisiana. This deviation
will test a change to the drawbridge
operation schedule to determine
whether a permanent change to the
schedule is needed. The deviation will
allow the draw of the Stephensville
Bridge to open on signal if at least one
hour of advance notice is given. During
the advance notice period, the draw
shall open on less than one hour notice
for an emergency and shall open on
demand should a temporary surge in
waterway traffic occur.
DATES: This deviation is effective from
October 5, 2007 until April 2, 2008.
ADDRESSES: You may mail comments
and related material to Commander
(dpb), Eighth Coast Guard District, 500
Poydras Street, New Orleans, Louisiana
70130–3310. The Commander, Eighth
Coast Guard District, Bridge
Administration Branch maintains the
public docket for this rulemaking.
Comments and material received from
the public, as well as documents
indicated in this preamble as being
available in the docket, will become part
of this docket and will be available for
inspection or copying at the Bridge
Administration office between 7 a.m.
and 3 p.m., Monday through Friday,
except Federal holidays.
FOR FURTHER INFORMATION CONTACT:
Bart
Marcules, Bridge Administration
Branch, telephone (504) 671–2128.
SUPPLEMENTARY INFORMATION:
VerDate Aug<31>2005
15:23 Oct 04, 2007
Jkt 214001
PO 00000
Frm 00016
Fmt 4700
Sfmt 4700
A Notice of Proposed Rule Making
[CGD08–07–023], is being issued in
conjunction with this Temporary
Deviation to obtain public comments.
The Coast Guard will evaluate public
comments from this Temporary
Deviation and the above referenced
Notice of Proposed Rule Making to
determine if a permanent special
drawbridge operating regulation is
warranted.
In accordance with 33 CFR 117.35(e),
the drawbridge must return to its regular
operating schedule immediately at the
end of the designated time period. This
deviation from the operating regulations
is authorized under 33 CFR 117.35.
Dated: September 21, 2007.
David M. Frank,
Bridge Administrator.
[FR Doc. 07–4860 Filed 10–4–07; 8:45 am]
BILLING CODE 4910–15–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
33 CFR Part 165
[COTP LA–LB 07–004]
RIN 1625–AA00
Safety Zone; Queensway Bay, Long
Beach, CA
Coast Guard, DHS.
Temporary final rule.
AGENCY:
ACTION:
SUMMARY: The Coast Guard is
establishing a temporary safety zone in
the Long Beach Harbor to encompass
the waters between Queensway Bay to
Island White at Long Beach harbor for
the Annual Los Angeles and Long Beach
Tug Boat Race. This safety zone is
needed to prevent vessels from
transiting the area during the race in
order to protect vessels and personnel
from potential damage and injury. Entry
into this safety zone will be prohibited
unless specifically authorized by the
Captain of the Port, Los Angeles-Long
Beach, or his on-scene representative.
DATES: This rule is effective from 5 p.m.
to 7 p.m. on September 27, 2007.
ADDRESSES: Documents indicated in this
preamble as being available in the
docket are part of docket COTP LA–LB
07–004 and are available for inspection
or copying at Sector Los Angeles—Long
Beach, 1001 S. Seaside Ave, San Pedro,
CA 90731 between 8 a.m. and 4 p.m.,
Monday through Friday, except Federal
holidays.
FOR FURTHER INFORMATION CONTACT:
Lieutenant Commander Peter Gooding,
E:\FR\FM\05OCR1.SGM
05OCR1
]]>Agencies
[Federal Register Volume 72, Number 193 (Friday, October 5, 2007)]
[Rules and Regulations]
[Pages 56896-56898]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-19732]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 556 and 558
New Animal Drugs; Ractopamine
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is amending the animal
drug regulations to reflect approval of a supplemental new animal drug
application (NADA) filed by Elanco Animal Health. The supplemental NADA
provides for an increased level of monensin in four-way combination
Type C medicated feeds containing ractopamine, melengestrol, monensin,
and tylosin for heifers fed in confinement for slaughter, a revision to
bacterial pathogen nomenclature, and an increase in liver tolerance.
DATES: This rule is effective October 5, 2007.
FOR FURTHER INFORMATION CONTACT: Suzanne J. Sechen, Center for
Veterinary Medicine (HFV-126), Food and Drug Administration, 7500
Standish Pl., Rockville, MD 20855, 301-827-0221, e-mail:
suzanne.sechen@cvm.fda.gov.
SUPPLEMENTARY INFORMATION: Elanco Animal Health, A Division of Eli
Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285, filed a
supplement to NADA 141-233 that provides for use of OPTAFLEXX
(ractopamine hydrochloride), MGA (melengestrol acetate), RUMENSIN
(monensin), and TYLAN (tylosin phosphate) Type A medicated articles to
[[Page 56897]]
make dry and liquid four-way combination Type C medicated feeds used
for increased rate of weight gain, improved feed efficiency, and
increased carcass leanness; for prevention and control of coccidiosis
due to Eimeria bovis and E. zuernii; for suppression of estrus (heat);
and for reduction of incidence of liver abscesses caused by
Fusobacterium necrophorum and Arcanobacterium (Actinomyces) pyogenes in
heifers fed in confinement for slaughter during the last 28 to 42 days
on feed. The supplemental NADA provides for an increased level of
monensin in four-way combination Type C medicated feeds containing
ractopamine, melengestrol, monensin, and tylosin for heifers fed in
confinement for slaughter, a revision to bacterial pathogen
nomenclature, and an increase in the cattle liver tolerance. The
supplemental NADA is approved as of September 11, 2007, and the
regulations in 21 CFR 556.420 and 558.500 are amended to reflect the
approval.
In accordance with the freedom of information provisions of 21 CFR
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and
effectiveness data and information submitted to support approval of
this application may be seen in the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
The agency has determined under 21 CFR 25.33(a)(2) that this action
is of a type that does not individually or cumulatively have a
significant effect on the human environment. Therefore, neither an
environmental assessment nor an environmental impact statement is
required.
This rule does not meet the definition of ``rule'' in 5 U.S.C.
804(3)(A) because it is a rule of ``particular applicability.''
Therefore, it is not subject to the congressional review requirements
in 5 U.S.C. 801-808.
List of Subjects
21 CFR Part 556
Animal drugs, Foods.
21 CFR Part 558
Animal drugs, Animal feeds.
0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under the
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR parts 556 and
558 are amended as follows:
PART 556--TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD
0
1. The authority citation for 21 CFR part 556 continues to read as
follows:
Authority: 21 U.S.C. 342, 360b, 371.
0
2. In Sec. 556.420, revise paragraph (b)(1) to read as follows:
Sec. 556.420 Monensin.
* * * * *
(b) * * *
(1) Cattle--(i) Liver. 0.10 part per million (ppm).
(ii) Muscle, kidney, and fat. 0.05 ppm.
(iii) Milk. Not required.
* * * * *
PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
0
3. The authority citation for 21 CFR part 558 continues to read as
follows:
Authority: 21 U.S.C. 360b, 371.
0
4. In Sec. 558.500, in the table in paragraph (e)(2), revise paragraph
(e)(2)(x) and add paragraph (e)(2)(xi) to read as follows:
Sec. 558.500 Ractopamine.
* * * * *
(e) * * *
(2) * * *
----------------------------------------------------------------------------------------------------------------
Ractopamine in Combination in grams/
grams/ton ton Indications for use Limitations Sponsor
----------------------------------------------------------------------------------------------------------------
* * * * * * *
----------------------------------------------------------------------------------------------------------------
(x) 9.8 to 24.6 Monensin 10 to 40 to Heifers fed in confinement for As in paragraph (e)(2)(vi) 000986
provide 0.14 to slaughter: As in paragraph of this section; see
0.42 mg monensin/lb (e)(2)(vi) of this section; paragraphs Sec. Sec.
of body weight, for prevention and control of 558.342(d), 558.355(d) and
depending on coccidiosis due to Eimeria 558.625(c) of this
severity of bovis and E. zuernii; for chapter. Melengestrol
coccidiosis reduction of incidence of acetate as provided by No.
challenge, up to liver abscesses caused by 000009 in Sec.
480 mg/head/day, Fusobacterium necrophorum and 510.600(c) of this
plus tylosin 8 to Arcanobacterium (Actinomyces) chapter.
10, plus pyogenes; and for suppression
melengestrol of estrus (heat).
acetate to provide
0.25 to 0.5 mg/head/
day
----------------------------------------------------------------------------------------------------------------
(xi) 9.8 to 24.6 Monensin 10 to 30, Heifers fed in confinement for As in paragraph (e)(2)(vi) 021641
plus tylosin 8 to slaughter: As in paragraph of this section; see
10, plus (e)(2)(vi) of this section; paragraphs Sec. Sec.
melengestrol for prevention and control of 558.342(d), 558.355(d) and
acetate to provide coccidiosis due to Eimeria 558.625(c) of this
0.25 to 0.5 mg/ bovis and E. zuernii; for chapter. Melengestrol
head/day reduction of incidence of acetate as provided by No.
liver abscesses caused by 021641 in Sec.
Fusobacterium necrophorum and 510.600(c) of this
Actinomyces (Corynebacterium) chapter.
pyogenes; and for suppression
of estrus (heat).
----------------------------------------------------------------------------------------------------------------
[[Page 56898]]
Dated: September 26, 2007.
Bernadette Dunham,
Deputy Director, Center for Veterinary Medicine.
[FR Doc. E7-19732 Filed 10-4-07; 8:45 am]
BILLING CODE 4160-01-S
